| INTERNATIONAL STEM CELL CORPORATION Patent applications |
| Patent application number | Title | Published |
|---|
| 20120100110 | PHYSIOLOGICAL METHODS FOR ISOLATION OF HIGH PURITY CELL POPULATIONS - The disclosure provides methods for isolating a pure or enriched population of differentiated cells derived from stem cells, comprising differentiating the population of stem cells; and migrating the differentiated cells through a porous membrane in a differentiation device to isolate the pure or enriched population of differentiated cells. The disclosure also provides a differentiation device for isolating a pure or enriched population of differentiated cells derived from stem cells, the device comprising a porous membrane; and an extracellular matrix. | 04-26-2012 |
| 20120070419 | METHOD OF ALTERING THE DIFFERENTIATIVE STATE OF A CELL AND COMPOSITIONS THEREOF - The present invention provides a method of altering the differentiative state of cells utilizing innovative protein expression constructs encoding transcription factors. The methods and compositions described herein may be used to generate induced pluripotent stem (iPS) cells, as well as differentiate, transdifferentiate or dedifferentiate cells of various epigenetic status. The method includes introduction of a nucleic acid construct, or expression product thereof, into a cell, and culture of the cell under culture conditions that efficiently converts the cell into a pluripotent cell, enhances the retention of the pluripotent state or efficiently converts the cell into a cell of a cell lineage corresponding to endoderm, mesoderm or ectoderm. | 03-22-2012 |
| 20100173414 | Methods of Deriving Differentiated Cells from Stem Cells - The present invention provides a method of generating definitive endoderm, mesoderm, or ectoderm cells. The method includes culturing embryonic stem cells, parthenogenetic cells, or induced pluripotent stem cells in the presence of a demethylation agent, a histone deacetylase inhibitor, or a combination thereof, and thereafter, culturing the stem cells in the absence of the agent or combination of agents, to produce definitive endoderm cells, mesoderm, or ectoderm cells. | 07-08-2010 |
| 20080299091 | Patient-specific stem cell lines derived from human parthenogenetic blastocysts - Methods are disclosed for generating HLA homozygous parthenogenetic human stem cell (hpSC-Hhom) lines from both HLA homozygous and HLA heterozygous donors. These hpSC-Hhom lines demonstrate typical human embryonic stem cell morphology, expressing appropriate stem cell markers and possessing high levels of alkaline phosphatase and telomerase activity. Additionally, injection of these cell lines into immunodeficient animals leads to teratoma formation. Furthermore, in the case of HLA heterozygous donors, the hpSC-Hhom lines inherit the haplotype from only one of the donor's parents. SNP data analysis suggests that hpSC-Hhom lines derived from HLA heterozygous oocyte donors are homozygous throughout the genome as assessed by single-nucleotide polymorphism (SNP) analysis. The protocol as disclosed minimizes the use of animal-derived components, which makes the stem cells more practical for clinical application. | 12-04-2008 |
